Vaxcyte
Developer of high-valency bacterial vaccine candidates using cell-free protein synthesis.
$59.50
After-hours close−0.31 (−0.52%)
At close$59.81(−2.20%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$2.12 | — | — |
| Aug 2026 | −$2.06 | −$1.97 | +4.4% |
| May 2026 | −$1.77 | −$2.30 | −29.7% |
| Feb 2026 | −$1.53 | −$1.80 | −17.7% |
| Nov 2025 | −$1.27 | −$1.56 | −22.8% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$2.12 | — | — | $12.5M | — | — |
| Aug 5, 2026 | −$2.06 | −$1.97 | +4.4% | $12.5M | — | — |
| May 6, 2026 | −$1.77 | −$2.30 | −29.7% | $12.5M | — | — |
| Feb 24, 2026 | −$1.53 | −$1.80 | −17.7% | $18.8M | — | — |
| Nov 4, 2025 | −$1.27 | −$1.56 | −22.8% | — | — | — |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | ||||||
| Aug 6, 2025 | ||||||
| May 7, 2025 | ||||||
| Feb 25, 2025 | ||||||
| Nov 5, 2024 | ||||||
| Aug 6, 2024 | ||||||
| May 8, 2024 | ||||||
| Feb 27, 2024 | ||||||
| Nov 6, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 8, 2023 | ||||||
| Feb 27, 2023 | ||||||
| Nov 7, 2022 | ||||||
| Aug 8, 2022 | ||||||
| May 9, 2022 | ||||||
| Feb 28, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 11, 2021 | ||||||
| May 11, 2021 | ||||||
| Mar 29, 2021 | ||||||
| Nov 12, 2020 | ||||||
| Aug 12, 2020 | ||||||
| Jun 15, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Sep 30, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Mar 31, 2019 | ||||||